Patient demographics and baseline characteristics
| . | All patients, N = 26 . | AML, n = 24 . | ALL, n = 2 . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 76.5 (26-90) | 76.0 (26-88) | 84.5 (79-90) |
| Age ≥75, n (%) | 17 (65.4) | 15 (62.5) | 2 (100.0) |
| Age ≥80, n (%) | 9 (34.6) | 8 (33.3) | 1 (50.0) |
| Sex, n (%) | |||
| M | 14 (53.8) | 12 (50.0) | 2 (100.0) |
| F | 12 (46.2) | 12 (50.0) | 0 (0.0) |
| Leukemia type, n (%) | |||
| AML | 24 (92.3) | ||
| ALL | 2 (7.7) | ||
| AML status, n (%) | |||
| Refractory | 6 (25.0) | ||
| Relapse | 4 (16.7) | ||
| Newly diagnosed, unfit for standard therapy | 14 (58.3) | ||
| De novo | 3 (21.4) | ||
| Secondary to MDS | 8 (57.1) | ||
| Secondary to MPD | 3 (21.4) | ||
| ELN score, n (%) | |||
| Favorable | 1 (4.2) | ||
| Intermediate | 14 (58.3) | ||
| Adverse | 9 (37.5) | ||
| ECOG PS, n (%) | |||
| 0 | 9 (34.6) | 9 (37.5) | 0 (0.0) |
| 1 | 14 (53.8) | 12 (50.0) | 2 (100.0) |
| 2 | 3 (11.5) | 3 (12.5) | 0 (0.0) |
| BM blast percentage | |||
| Median (range) | 83.0 (22-100) | 83.0 (22-100) | 68.5 (48-89) |
| 20%-30%, n (%) | 1 (3.8) | 1 (4.2) | 0 (0.0) |
| 31%-50%, n (%) | 4 (15.4) | 3 (12.5) | 1 (50.0) |
| >50%, n (%) | 19 (73.1) | 18 (75.0) | 1 (50.0) |
| White blood cells, ×109/L | |||
| Median | 7.2 | 8.2 | 1.8 |
| Range | 0.8-104 | 0.8-104 | 1.7-2.0 |
| . | All patients, N = 26 . | AML, n = 24 . | ALL, n = 2 . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 76.5 (26-90) | 76.0 (26-88) | 84.5 (79-90) |
| Age ≥75, n (%) | 17 (65.4) | 15 (62.5) | 2 (100.0) |
| Age ≥80, n (%) | 9 (34.6) | 8 (33.3) | 1 (50.0) |
| Sex, n (%) | |||
| M | 14 (53.8) | 12 (50.0) | 2 (100.0) |
| F | 12 (46.2) | 12 (50.0) | 0 (0.0) |
| Leukemia type, n (%) | |||
| AML | 24 (92.3) | ||
| ALL | 2 (7.7) | ||
| AML status, n (%) | |||
| Refractory | 6 (25.0) | ||
| Relapse | 4 (16.7) | ||
| Newly diagnosed, unfit for standard therapy | 14 (58.3) | ||
| De novo | 3 (21.4) | ||
| Secondary to MDS | 8 (57.1) | ||
| Secondary to MPD | 3 (21.4) | ||
| ELN score, n (%) | |||
| Favorable | 1 (4.2) | ||
| Intermediate | 14 (58.3) | ||
| Adverse | 9 (37.5) | ||
| ECOG PS, n (%) | |||
| 0 | 9 (34.6) | 9 (37.5) | 0 (0.0) |
| 1 | 14 (53.8) | 12 (50.0) | 2 (100.0) |
| 2 | 3 (11.5) | 3 (12.5) | 0 (0.0) |
| BM blast percentage | |||
| Median (range) | 83.0 (22-100) | 83.0 (22-100) | 68.5 (48-89) |
| 20%-30%, n (%) | 1 (3.8) | 1 (4.2) | 0 (0.0) |
| 31%-50%, n (%) | 4 (15.4) | 3 (12.5) | 1 (50.0) |
| >50%, n (%) | 19 (73.1) | 18 (75.0) | 1 (50.0) |
| White blood cells, ×109/L | |||
| Median | 7.2 | 8.2 | 1.8 |
| Range | 0.8-104 | 0.8-104 | 1.7-2.0 |
F, female; HMA, hypomethylating agents; M, male; MPD, myeloproliferative disorders.